Prevalence and Influence Factors for Non-Alcoholic Fatty Liver Disease in Long-Term Hospitalized Patients with Schizophrenia: A Cross-Sectional Retrospective Study

被引:3
作者
Li, Xuelong [1 ,2 ,3 ]
Gao, Yakun [4 ]
Wang, Yongmei [2 ,3 ,5 ]
Wang, Ying [2 ,3 ,5 ]
Wu, Qing [1 ,2 ,3 ,5 ]
机构
[1] Anhui Med Univ, Sch Mental Hlth & Psychol Sci, Hefei, Peoples R China
[2] Anhui Med Univ, Affiliated Psychol Hosp, Dept Psychiat, 316 Huangshan Rd, Hefei 230000, Peoples R China
[3] Anhui Mental Hlth Ctr, Hefei, Peoples R China
[4] Weifang Med Coll, Affiliated Hosp, Weifang, Peoples R China
[5] Hefei Fourth Peoples Hosp, Hefei, Peoples R China
关键词
schizophrenia; non-alcoholic fatty liver disease; prevalence; influence factors; long-term hospitalization; PSYCHIATRIC-PATIENTS; ANTIPSYCHOTIC-DRUGS; RISK; ASSOCIATION; MANAGEMENT; PREDICT; CYCLE; ACID;
D O I
10.2147/NDT.S398385
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: Long-term hospitalized patients with schizophrenia (SCZ) are vulnerable to physical illness, leading to impaired life expectancy and treatment outcomes. There are few studies on the influence of non-alcoholic fatty liver disease (NAFLD) in long-term hospitalized patients. This study aimed to investigate the prevalence of and influence factors for NAFLD in hospitalized patients with SCZ.Patients and Methods: This cross-sectional retrospective study included 310 patients who had experienced long-term hospitaliza-tion for SCZ. NAFLD was diagnosed based on the results of abdominal ultrasonography. The T-test, Mann-Whitney U-test, correlation analysis, and logistic regression analysis were used to determine the influence factors for NAFLD.Results: Among the 310 patients who had experienced long-term hospitalization for SCZ, the prevalence of NAFLD was 54.84%. Antipsychotic polypharmacy (APP), body mass index (BMI), hypertension, diabetes, total cholesterol (TC), apolipoprotein B (ApoB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), triglycerides (TG), uric acid, blood glucose, gamma-glutamyl transpeptidase (GGT), high-density lipoprotein, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio significantly differed between the NAFLD and non-NAFLD groups (all P<0.05). Hypertension, diabetes, APP, BMI, TG, TC, AST, ApoB, ALT, and GGT were positively correlated with NAFLD (all P<0.05). The results of the logistic regression analysis indicated that APP, diabetes, BMI, ALT, and ApoB were the influence factors for NAFLD in patients with SCZ.Conclusion: Our results suggest a high prevalence of NAFLD among patients hospitalized long-term due to severe SCZ symptoms. Moreover, a history of diabetes, APP, overweight/obese status, and increased levels of ALT and ApoB were identified as negative factors for NAFLD in these patients. These findings may provide a theoretical basis for the prevention and treatment of NAFLD in patients with SCZ and contribute to the development of novel targeted treatments.
引用
收藏
页码:379 / 389
页数:11
相关论文
共 57 条
  • [21] Risk of Nonalcoholic Fatty Liver Disease in Patients With Schizophrenia Treated With Antipsychotic Drugs A Cross-sectional Study
    Koreki, Akihiro
    Mori, Hiroko
    Nozaki, Shoko
    Koizumi, Teruki
    Suzuki, Hisaomi
    Onaya, Mitsumoto
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2021, 41 (04) : 474 - 477
  • [22] Microbiota and Fatty Liver Disease - the Known, the Unknown, and the Future
    Lang, Sonja
    Schnabl, Bernd
    [J]. CELL HOST & MICROBE, 2020, 28 (02) : 233 - 244
  • [23] Dose Equivalents for Antipsychotic Drugs: The DDD Method
    Leucht, Stefan
    Samara, Myrto
    Heres, Stephan
    Davis, John M.
    [J]. SCHIZOPHRENIA BULLETIN, 2016, 42 : S90 - S94
  • [24] Predictors of non-alcoholic fatty liver disease in children
    Li, Menglong
    Shu, Wen
    Zunong, Jiawulan
    Amaerjiang, Nubiya
    Xiao, Huidi
    Li, Dan
    Vermund, Sten H.
    Hu, Yifei
    [J]. PEDIATRIC RESEARCH, 2022, 92 (01) : 322 - 330
  • [25] Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study
    Ma, Qiuyue
    Yang, Fude
    Ma, Botao
    Jing, Wenzhan
    Liu, Jue
    Guo, Moning
    Li, Juan
    Wang, Zhiren
    Liu, Min
    [J]. HEPATOLOGY INTERNATIONAL, 2021, 15 (01) : 127 - 136
  • [26] Paraoxonase 1 activity and lipid profile in schizophrenic patients
    Mabrouk, Hajer
    Mechria, Haithem
    Mechri, Anouar
    Azizi, Islam
    Neffati, Fadoua
    Douki, Wahiba
    Gaha, Lotfi
    Najjar, Mohamed Fadhel
    [J]. ASIAN JOURNAL OF PSYCHIATRY, 2014, 9 : 36 - 40
  • [27] Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis
    Maher, Jacquelyn J.
    Leon, Pablo
    Ryan, James C.
    [J]. HEPATOLOGY, 2008, 48 (02) : 670 - 678
  • [28] Mechanisms Underlying Antipsychotic-Induced NAFLD and Iron Dysregulation: A Multi-Omic Approach
    May, Meghan
    Barlow, Deborah
    Ibrahim, Radwa
    Houseknecht, Karen L.
    [J]. BIOMEDICINES, 2022, 10 (06)
  • [29] Schizophrenia-An Overview
    McCutcheon, Robert A.
    Reis Marques, Tiago
    Howes, Oliver D.
    [J]. JAMA PSYCHIATRY, 2020, 77 (02) : 201 - 210
  • [30] All-cause and cause-specific mortality among people with severe mental illness in Brazil's public health system, 2000-15: a retrospective study
    Melo, Ana Paula Souto
    Dippenaar, Ilse N.
    Johnson, Sarah Charlotte
    Weaver, Nicole Davis
    Acurcio, Francisco de Assis
    Malta, Deborah Carvalho
    Ribeiro, Antonio Luiz P.
    Guerra Junior, Augusto Afonso
    Wool, Eve E.
    Naghavi, Mohsen
    Cherchiglia, Mariangela Leal
    [J]. LANCET PSYCHIATRY, 2022, 9 (10): : 771 - 781